Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TransCon CNP versus placebo in infants with achondroplasia
2023-506091-27-00Phase 2Authorised
- Sponsor
- Ascendis Pharma
- Start
- Sep 2024
- Modality
- Peptides, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 16
01
Overview
Phase 2, randomised, double-blind trial of navepegritide in achondroplasia (ACH) (3 arms), sponsored by Ascendis Pharma. Primary endpoints: Incidence of treatment-emergent adverse events over 52 weeks and Change from baseline to 52 weeks in length/height Z-score. Planned start Sep 2024; status: authorised.
02
Drugs
navepegritide
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on 2023-506091-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506091-27-00.